ScripPfizer’s recent exit from gene therapies was not an indictment of the safety and efficacy of gene and cellular therapies. Rather it was the latest example of the difficulties in commercializing these
ScripAnalysts have been queuing up to applaud MeiraGTx Holdings' innovative pact with artificial intelligence company Hologen which involves the establishment of a joint venture designed to get the UK/US
ScripPublic biopharma companies usually spend the week before the J.P. Morgan Healthcare Conference announcing new financings, partnerships and sometimes data so that they have compelling milestones to dis
ScripUniQure has reached an agreement with the US Food and Drug Administration on how it can proceed with seeking accelerated approval for AMT-130, a gene therapy in Phase I/II development for Huntington’s